PEG-Cyclosporine A Conjugates for Neutrophil Migration Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with neutrophil-mediated inflammation, such as inflammatory bowel disease and asthma, are limited in efficacy and specificity, particularly in addressing the underlying mechanisms of neutrophil migration and activation.
Innovation Solution
The development of compounds, including PEG-cyclosporine A conjugates, that inhibit specific targets like multidrug resistance protein 2 (MRP2) and formyl peptide receptor 1 (FPR1), alongside increasing N-acylethanolamines (NAEs), to reduce neutrophil migration into target tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neutrophil-mediated inflammation are used, then they can address general inflammatory conditions, but they lack specificity and efficacy in targeting underlying mechanisms of neutrophil migration and activation
Solution Approach 1:
The patent segments the inflammatory pathway into distinct targets: MRP2 transporter on epithelial cells, FPR1 receptors on neutrophils, and COX-2 enzyme. By developing compounds that specifically inhibit each target, the treatment addresses the disease mechanism in a segmented, targeted manner rather than using broad-spectrum anti-inflammatories, thereby improving efficacy and specificity simultaneously
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of cyclosporine A to create PEG-cyclosporine A conjugates with optimized pharmacokinetic properties. The PEGylation increases molecular weight and hydrophilicity, extending half-life and reducing immunogenicity, which improves treatment reliability while maintaining target specificity
2Reliability
If MRP2 is inhibited to prevent HXA3 transport into intestinal lumen, then neutrophil chemotaxis is reduced, but this requires highly specific compounds to avoid off-target effects
Solution Approach 1:
The patent uses PEG-cyclosporine A conjugates as intermediary compounds that indirectly inhibit MRP2 by blocking its substrate transport function. The conjugate acts as a mediator that interacts with the MRP2-HXA3 pathway without requiring direct binding to MRP2, thereby achieving the anti-inflammatory effect while reducing the need for extremely high inhibitor specificity
Solution Approach 2:
The patent creates PEG-cyclosporine A conjugates that copy the immunosuppressive properties of cyclosporine A while adding PEG chains to enhance solubility and stability. This copying approach allows the compound to maintain its biological activity against inflammatory pathways while improving its pharmacological profile for targeted MRP2 inhibition
3Reliability
If FPR1 is inhibited to block gliadin-induced neutrophil attraction, then gut permeability increases, but achieving this requires compounds with high target selectivity
Solution Approach 1:
The patent segments the neutrophil recruitment pathway by specifically targeting FPR1 receptors on neutrophils separately from other inflammatory pathways. By developing compounds that selectively bind to FPR1, the treatment addresses gliadin-induced neutrophil attraction with high specificity, improving reliability while maintaining manufacturing precision through targeted receptor interaction
Solution Approach 2:
The patent modifies the pharmacological parameters of cyclosporine A through PEGylation, creating conjugates with altered binding characteristics that enhance selectivity for FPR1 receptors. This parameter change approach allows the compound to achieve high receptor binding specificity while maintaining the desired neutrophil migration inhibition effect
Data Source
AI summary
Disclosed herein are cyclosporine compounds and methods for use in the treatment or prevention of neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPR1.